The present study was prompted by an earlier observation in this laboratory that patients with leuko-agglutinins (LA) were apt to develop transfusion reactions. It was noted that 13 of 32 patients, or 41 %, had had marked and repeated febrile transfusion reactions. In the course of other work in this area, Dausset, Goudsmith and van Loghem, Marchai et al., and Mendes de Leon all called attention to the susceptibility of patients with LA to febrile transfusion reactions. To both confirm and extend the view that LA might be a significant factor in the etiology of the unexplained febrile transfusion reaction, we have pursued three lines of investigation. First, a group of sera from patients with transfusion reactions were examined for LA; second, patients receiving repeated transfusion therapy were followed for the development of both transfusion reactions and LA; and third, to determine if a febrile reaction could be prevented, these patients were treated with blood from which the majority of leukocytes had been removed.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.